Pharmaceuticals(53)

  • Imaging Platform for IBD Drug Discovery (No. T4-1925)

    Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the gastrointestinal (GI) tract, resulting in its damage and gut barrier dysfunction. ... Read more
    Associate Professor Eran Elinav

    Eran Elinav

    Faculty of Biology

    5746
  • Imaging Platform for IBD Drug Discovery (No. T4-1925)

    Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the gastrointestinal (GI) tract, resulting in its damage and gut barrier dysfunction. ... Read more
    Extension Service Benjamin Geiger

    Benjamin Geiger

    Faculty of Biology

    5746
  • Protein Based Treatment for Duchene Muscular Dystrophy and Cancer (No. T4-1913)

    Duchenne muscular dystrophy (DMD) is a disease that affects approximately 1 in 3,500 boys with a life expectancy of ~26 years. ... Read more
    Full Professor Irit Sagi

    Irit Sagi

    Faculty of Biology

    6026
  • Early Detection and Treatment of Myeloid Leukemia (No. T4-1896)

    malignancies such as AML and MDS are usually aggressive and have a low overall survival rate. Recent studies demonstrated that specific mutations in hematopoietic stem cells occur years before the disease is diagnosed in individuals at high risk of developing myeloid malignancies. ... Read more
    Senior Scientist Liran Shlush

    Liran Shlush

    Faculty of Biology

    6166
  • Person-specific Assessment of Probiotics Responsiveness (No. T4-1895)

    Probiotics are a widely consumed dietary supplement, however, their efficacy is controversial and not all individuals benefit from their use. Therefore, a predictive tool that distinguishes between probiotic-permissive and resistant individuals is needed. ... Read more
    Full Professor Eran Segal

    Eran Segal

    Faculty of Mathematics and Computer Science

    5734
  • Person-specific Assessment of Probiotics Responsiveness (No. T4-1895)

    Probiotics are a widely consumed dietary supplement, however, their efficacy is controversial and not all individuals benefit from their use. Therefore, a predictive tool that distinguishes between probiotic-permissive and resistant individuals is needed. ... Read more
    Associate Professor Eran Elinav

    Eran Elinav

    Faculty of Biology

    5734
  • Preventing Biofilm Formation by Enzyme Inhibitors (No. T4-1893)

    Biofilm is a complex colony of bacteria, which are attached together by extracellular polymeric substance. This setting provides the bacteria protection against environmental factors, improves their surface attachment, and plays a major role in resistance to treatment. ... Read more
    Senior Scientist ILANA Kolodkin-Gal

    ILANA Kolodkin-Gal

    Faculty of Biochemistry

    5731
  • Universal CAR-Ts for Treating Cancer (No. T4-1884)

    Chimeric Antigen Receptor T-Cells (CAR-Ts) are one of the revolutionary technologies of the twenty-first century, invented by Prof. Zelig Eshhar at the Weizmann Institute of Science. ... Read more
    Emeritus Zelig Eshhar

    Zelig Eshhar

    Faculty of Biology

    5722
  • Covalent Inhibitors for Treatment of Inflammation and Neurodegeneration (No. T4-1880)

    C-Jun NH2-terminal kinase (JNK) plays an integral role in many cellular processes and is associated with the pathophysiology of a number of neurological, inflammatory, and autoimmune diseases. ... Read more
    Senior Scientist Nir London

    Nir London

    Faculty of Chemistry

    6109
  • Treatment of Psychiatric Disorders by Inhibiting Importin Alpha 5 (No. T4-1875)

    Anxiety and stress-related conditions pose a significant health burden on modern healthcare systems. While currently, available anxiolytic drugs can be highly effective for some patients, their long-term use is limited by their potentially severe and debilitating side effects. The group of Prof. ... Read more
    Full Professor Michael Fainzilber

    Michael Fainzilber

    Faculty of Biochemistry

    5719

Pages

Subscribe to Pharmaceuticals